AngioDynamics, Inc. (ANGO)
12.36
+0.34
(+2.87%)
USD |
NASDAQ |
Oct 23, 16:00
12.37
0.00 (0.00%)
After-Hours: 20:00
AngioDynamics Enterprise Value : 501.34M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 501.34M |
| October 22, 2026 | 486.71M |
| October 21, 2026 | 481.19M |
| October 20, 2026 | 477.80M |
| October 19, 2026 | 459.98M |
| October 16, 2026 | 453.62M |
| October 15, 2026 | 468.04M |
| October 14, 2026 | 445.56M |
| October 13, 2026 | 439.19M |
| October 12, 2026 | 460.40M |
| October 09, 2026 | 465.50M |
| October 08, 2026 | 453.19M |
| October 07, 2026 | 578.77M |
| October 06, 2026 | 588.53M |
| October 05, 2026 | 636.04M |
| October 02, 2026 | 617.80M |
| October 01, 2026 | 618.22M |
| September 30, 2026 | 629.25M |
| September 29, 2026 | 638.59M |
| September 28, 2026 | 636.04M |
| September 25, 2026 | 633.92M |
| September 24, 2026 | 625.01M |
| September 23, 2026 | 634.77M |
| September 22, 2026 | 641.56M |
| September 21, 2026 | 630.95M |
| Date | Value |
|---|---|
| September 18, 2026 | 631.80M |
| September 17, 2026 | 628.83M |
| September 16, 2026 | 632.65M |
| September 15, 2026 | 641.98M |
| September 14, 2026 | 634.77M |
| September 11, 2026 | 624.59M |
| September 10, 2026 | 623.31M |
| September 09, 2026 | 626.71M |
| September 08, 2026 | 622.47M |
| September 04, 2026 | 621.62M |
| September 03, 2026 | 633.07M |
| September 02, 2026 | 639.44M |
| September 01, 2026 | 649.62M |
| August 31, 2026 | 661.07M |
| August 28, 2026 | 618.04M |
| August 27, 2026 | 615.12M |
| August 26, 2026 | 611.37M |
| August 25, 2026 | 622.21M |
| August 24, 2026 | 614.71M |
| August 21, 2026 | 613.87M |
| August 20, 2026 | 616.79M |
| August 19, 2026 | 627.22M |
| August 18, 2026 | 616.79M |
| August 17, 2026 | 610.54M |
| August 14, 2026 | 618.04M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Boston Scientific Corp. | 78.32B |
| Globus Medical, Inc. | 10.45B |
| Penumbra, Inc. | 12.33B |
| Abbott Laboratories | 207.10B |
| Alphatec Holdings, Inc. | 2.205B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.097M |
| Revenue (Quarterly) | 80.92M |
| Total Expenses (Quarterly) | 88.01M |
| EPS Diluted (Quarterly) | -0.1689 |
| Gross Profit Margin (Quarterly) | 56.00% |
| Profit Margin (Quarterly) | -8.77% |
| Earnings Yield | -6.39% |
| Normalized Earnings Yield | -4.148 |